In BCR::ABL1+ (breakpoint cluster region:: abelson tyrosine kinase 1) ALL, pharmacological EZR inhibition synergizes strongly with dasatinib and imatinib, demonstrating potential as a combination therapy. This evidence concerns the gene BCR and acute lymphoblastic leukemia.